Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies

• Published in: Cancer science Vol. 112; no. 4; pp. 1357 - 1368
• Main Authors: Guo, Zhenling, Tu, Sanfang, Yu, Siyao, Wu, Liufang, Pan, Wanying, Chang, Ning, Zhou, Xuan, Song, Chaoyang, Li, Yuhua, He, Yanjie
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.04.2021; John Wiley and Sons Inc
• Subjects: Animals; antigen loss; Antigens; Antigens, Neoplasm - immunology; CD123 antigen; CD19 antigen; CD20 antigen; CD22 antigen; Cell therapy; chimeric antigen receptor; Chimeric antigen receptors; Cytokines; Cytotoxicity; dual‐target; Hematologic Neoplasms - immunology; Hematologic Neoplasms - therapy; hematological malignancies; Hematology; Humans; Immunotherapy; Immunotherapy - methods; Leukemia; Lymphocytes; Lymphocytes T; Lymphoma; Medical prognosis; Mutation; Peptides; Receptors, Antigen, T-Cell - immunology; Receptors, Chimeric Antigen - immunology; relapse; Response rates; Review; T-Lymphocytes - immunology; Tumors; hematological malignancies; dual-target; chimeric antigen receptor; antigen loss; relapse

In recent years, the excellent curative effect of CD19‐specific chimeric antigen receptor (CAR) T‐cell therapy has brought hope to patients with relapsing or refractory B‐cell hematological malignancies, however relapse after CAR T‐cell infusion has hindered the widespread clinical application of th...